Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"IsomAb","sponsor":"Broadview Ventures","pharmaFlowCategory":"D","amount":"$9.4 million","upfrontCash":"Undisclosed","newsHeadline":"IsomAb Announces Close of \u00a37.5 Million Financing to Accelerate Lead Candidate for Treatment of Peripheral Arterial Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by IsomAb

    Menu

    IsomAb

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              IsomAb

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IsomAb Announces Close of £7.5 Million Financing to Accelerate Lead Candidate for Treatment of Peripheral Arterial Disease

              Details:

              The financing will enable the company to progress in the development of lead compound ISM-001, which is a high affinity, neutralising antibody that specifically binds VEGF165b for the treatment of peripheral arterial disease.

              Lead Product(s): ISM-001

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: ISM-001

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Broadview Ventures

              Deal Size: $9.4 million Upfront Cash: Undisclosed

              Deal Type: Financing February 20, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY